Pharma MarPHMMF -25.35%82 Days Payable is 1,063.45 as of Mar. 2026, which is 18% above its 10-year median of 901.99. GuruFocus rates PHMMF with a GF Score™ of 82/100 and a GF Value™ of $91.39 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 707 Biotechnology companies, Pharma Mar ranks better than 85.29% on this metric.
Pharma Mar's average Accounts Payable for the
three
months ended in Mar. 2026 was $49.3 Mil. Pharma Mar's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $4.2 Mil.
Hence, Pharma Mar's Days Payable for the
three
months ended in Mar. 2026 was 1,063.45.
The historical rank and industry rank for Pharma Mar's Days Payable or its related term are showing as below:
PHMMF'
s Days Payable Range Over the Past 10 Years
Min: 280.54 Med: 901.99 Max: 2485
Current: 934.24
During the past 13 years, Pharma Mar's highest Days Payable was 2485.00. The lowest was 280.54. And the median was 901.99.
PHMMF's Days Payable is ranked better than 85.29% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs PHMMF: 934.24
Pharma Mar's Days Payable
declined
from Mar. 2025 (1,065.60) to Mar. 2026 (1,063.45).
It may suggest that Pharma Maraccelerated paying its suppliers.
Pharma Mar Days Payable Related Terms
Pharma Mar Days Payable Historical Data
* Premium members only.
The historical data trend for Pharma Mar's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHMMF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Pharma Mar's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's Days Payable distribution charts can be found below:
* The bar in red indicates where Pharma Mar's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pharma Mar's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar (PHMMF) has a Days Payable of 1,063.45 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharma Mar and its competitors. This is 18% above median its historical median of 901.99. Over the past decade, Pharma Mar's Days Payable has ranged from 280.54 to 2,485.00. According to the industry distribution chart, Pharma Mar ranks #104 out of 707 companies in the Biotechnology industry, placing it in the top 14.7%.
Is Pharma Mar's Days Payable too high?
Pharma Mar's current Days Payable of 1,063.45 is 18% above median its 10-year median of 901.99. Over the past 10 years, this metric has ranged from a low of 280.54 to a high of 2,485.00. The Biotechnology industry median Days Payable is 113.76. Pharma Mar's value of 1,063.45 is 834.8% above this industry median. Based on the distribution chart, Pharma Mar ranks #104 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Mar has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #104 out of 707 companies for Days Payable. This places Pharma Mar in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Pharma Mar's value of 1,063.45 is 834.8% above this benchmark. Historically, Pharma Mar's own Days Payable has ranged from 280.54 to 2,485.00 over the past decade. While the company's 10-year median is 901.99 vs. the industry median of 113.76, Pharma Mar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Mar's current Days Payable of 1,063.45 is 834.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharma Mar and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Mar's current Days Payable is 1,063.45, which is 18% above median its own 10-year median of 901.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.39, compared to a current price of $79.49 — trading 13% below its estimated fair value. The current Days Payable is 1,063.45, which is 18% above median its 10-year median of 901.99 and 834.8% above the Biotechnology industry median of 113.76. Pharma Mar's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current Days Payable is 1,063.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (PHMMF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of $79.49 is trading 13% below its estimated GF Value™ of $91.39.
GuruFocus considers Pharma Mar to be Modestly Undervalued.
Key valuation signals for PHMMF:
Days Payable: 1,063.45 (18% above median its 10-year median of 901.99)
GF Value™: $91.39 vs. price of $79.49 (13% below fair value)
Industry Position: 834.8% above the Biotechnology median (#104 of 707)
No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
82GF Score
Get the complete analysis for PHMMF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHMMF has been successfully added to your 
